Key Words: prostate, prostatic neoplasms, prostate specific antigen, diagnosis, mass screening

Size: px
Start display at page:

Download "Key Words: prostate, prostatic neoplasms, prostate specific antigen, diagnosis, mass screening"

Transcription

1 A Multicenter Study of [-2]Pro-Prostate Specific Antigen Combined With Prostate Specific Antigen and Free Prostate Specific Antigen for Prostate Cancer Detection in the 2.0 to 10.0 ng/ml Prostate Specific Antigen Range William J. Catalona,*, Alan W. Partin, Martin G. Sanda, John T. Wei, George G. Klee, Chris H. Bangma, Kevin M. Slawin, Leonard S. Marks, Stacy Loeb, Dennis L. Broyles, Sanghyuk S. Shin, Amabelle B. Cruz, Daniel W. Chan, Lori J. Sokoll, William L. Roberts, Ron H. N. van Schaik and Isaac A. Mizrahi From the Department of Urology, Northwestern University Feinberg School of Medicine (WJC), Chicago, Illinois, Departments of Urology (AWP, SL) and Pathology (DWC, LJS), The Johns Hopkins University School of Medicine, Baltimore, Maryland, Division of Urology, Beth Israel Deaconess Medical Center, Harvard Medical School (MGS), Boston, Massachusetts, Department of Urology, University of Michigan School of Medicine (JTW), Ann Arbor, Michigan, Department of Pathology, Mayo Clinic (GGK), Rochester, Minnesota, Departments of Urology (CHB) and Clinical Chemistry (RHNvS), Erasmus University Medical Center, Rotterdam, The Netherlands, Vanguard Urologic Institute and Texas Prostate Center (KMS), Houston, Texas, Department of Urology, University of California-Los Angeles (LSM), Los Angeles, California, Beckman Coulter, Inc. (DLB, SSS, ABC, IAM), Carlsbad, California, and ARUP Laboratories, Department of Pathology, University of Utah (WLR), Salt Lake City, Utah Abbreviations and Acronyms DRE digital rectal examination fpsa free PSA NIH/NCI National Institutes of Health/National Cancer Institute p2psa [-2]proPSA PCa prostate cancer PHI prostate health index PSA prostate specific antigen Purpose: Prostate specific antigen and free prostate specific antigen have limited specificity to detect clinically significant, curable prostate cancer, leading to unnecessary biopsy, and detection and treatment of some indolent tumors. Specificity to detect clinically significant prostate cancer may be improved by [-2]pro-prostate specific antigen. We evaluated [-2]pro-prostate specific antigen, free prostate specific antigen and prostate specific antigen using the formula, ([-2]pro-prostate specific antigen/free prostate specific antigen prostate specific antigen 1/2 ) to enhance specificity to detect overall and high grade prostate cancer. Materials and Methods: We enrolled 892 men with no history of prostate cancer, normal rectal examination, prostate specific antigen 2 to 10 ng/ml and 6-core or greater prostate biopsy in a prospective multi-institutional trial. We examined the relationship of serum prostate specific antigen, free-to-total prostate specific antigen and the prostate health index with biopsy results. Primary end points were specificity and AUC using the prostate health index to detect overall and Gleason 7 or greater prostate cancer on biopsy compared with those of free-to-total prostate specific antigen. Results: In the 2 to 10 ng/ml prostate specific antigen range at 80% to 95% sensitivity the specificity and AUC (0.703) of the prostate health index exceeded those of prostate specific antigen and free-to-total prostate specific antigen. An increasing prostate health index was associated with a 4.7-fold increased risk of prostate cancer and a 1.61-fold increased risk of Gleason score greater than or equal to disease on biopsy. The AUC of the index exceeded that of free-to-total prostate specific antigen (0.724 vs 0.670) to discriminate prostate cancer with Gleason 4 or greater 3 from lower grade disease or negative biopsy. Prostate health index results were not associated with age and prostate volume. Conclusions: The prostate health index may be useful in prostate cancer screening to decrease unnecessary biopsy in men 50 years old or older with prostate specific antigen 2 to 10 ng/ml and negative digital rectal examination with minimal loss in sensitivity. Key Words: prostate, prostatic neoplasms, prostate specific antigen, diagnosis, mass screening /11/ /0 Vol. 185, , May 2011 THE JOURNAL OF UROLOGY Printed in U.S.A by AMERICAN UROLOGICAL ASSOCIATION EDUCATION AND RESEARCH, INC. DOI: /j.juro

2 [-2]PRO-PROSTATE SPECIFIC ANTIGEN FOR PROSTATE CANCER DETECTION 1651 Submitted for publication August 30, Study received institutional review board approval at each participating institution. Supported by NIH/NCI Johns Hopkins Prostate SPORE Grant P50CA58236, Early Detection Research Network NIH/NCI Grant U01-CA86323, NIH/NCI U01 CA86323 (AWP), U24 CA (DWC) and U01CA (MGS), Urological Research Foundation, Northwestern-University of Chicago Prostate SPORE Grant NIH/NCI P50 CA S2, Robert H. Lurie Comprehensive Cancer Center Grant NIH/NCI P30 CA60553, Beckman Coulter, Inc. (WJC) and Mayo Clinic Prostate SPORE Grant NIH/NCI CA (GGK). Presented at annual meeting of American Urological Association, San Francisco, California, June 2, Supplementary material for this article can be obtained at * Correspondence: Northwestern University Feinberg School of Medicine, 675 North St Clair St., Chicago, Illinois ( Financial interest and/or other relationship with Beckman Coulter, decode Genetics, OHMX and Nanosphere. Financial interest and/or other relationship with Beckman Coulter. Financial interest and/or other relationship with Sanofi-Aventis, Beckman Coulter, Envisioneering and American Medical Systems. Financial interest and/or other relationship with Beckman Coulter, Bellicum, Sanofi-Aventis, Allergan and Molecular Insights. Financial interest and/or other relationship with ARUP Laboratories. For another article on a related topic see page PROSTATE specific antigen testing was Food and Drug Administration approved using a 4.0 ng/ml cutoff to recommend prostate biopsy. Lower cutoffs further enhance early PCa detection 1 since PSA correlates with the risk of overall and high grade PCa at PSA less than 4 ng/ml. 2 However, PSA testing may be confounded by benign conditions. The low specificity at PSA less than 10 ng/ml has created a diagnostic gray zone in which PCa is found on biopsy in about 25% of patients. This is important since most PCa is curable at PSA less than 10 ng/ml while PSA greater than 10 ng/ml often portends advanced disease. 3 Serum PSA is complexed with proteins or circulates in an unbound form called fpsa. 4 At PSA 4.0 to 10.0 ng/ml the free-to-total PSA ratio significantly improves discrimination between PCa and benign conditions. 5 Different prostate regions contain varying proportions of fpsa isoforms, including propsa, which is associated with PCa. The primary form in PCa tissue is p2psa. 6 8 At PSA 2.0 to 10.0 ng/ml p2psa further improves specificity for PCa detection relative to the free-to-total PSA ratio The usefulness of p2psa at PSA less than 4.0 ng/ml and its relationship to PCa aggressiveness are relevant to the PCa screening debate, including concerns about over diagnosis and overtreatment Preliminary evidence suggests that higher percent p2psa may be associated with more aggressive PCa. 10,12,13,18 Selecting thresholds for clinical use of p2psa has received limited study. We evaluated the relationship of p2psa (the assay for which is not available in the United States), combined with fpsa and PSA in a mathematical formula called PHI, with PCa detection and tumor features. METHODS Study Design. We performed a multicenter, double-blind, casecontrol clinical trial to validate PHI in the 2.0 to 10.0 ng/ml PSA range. The formula was developed from an independent data set, 19 that is p2psa is measured in pg/ml and fpsa and PSA are measured in ng/ml. The study protocol was approved by the institutional review board at each participating institution and all participants provided informed consent. Population. We evaluated 1,372 men from a total of 8 medical centers from October 2003 to June The study cohort included men 50 years old or older who met certain criteria, including 1) no PCa history, 2) nonsuspicious DRE, 3) pre-study PSA 1.5 to 11.0 ng/ml, 4) 6-core or greater biopsy and 5) a histological diagnosis from prostate biopsy. Study exclusion criteria were 1) medications or surgical interventions that alter PSA before blood draw, 2) urinary infection at blood draw, 3) a final Access Hybritech PSA value outside the 2.0 to 10.0 ng/ml range, 4) no blood draw or biopsy at the appropriate time or 5) prior androgen replacement therapy. A total of 326 participants did not meet study eligibility requirements, such as no appropriate informed consent in 107, no PSA within 2 to 10 ng/ml in 92 and other study specific exclusions in 120. Seven men were excluded from analysis due to unevaluable tests from hemolyzed or hyperlipidemic samples, or p2psa duplicate results with a high coefficient of variation that could not be retested. Finally, at 1 site only 154 men 62 to 74 years old were enrolled. They were not included in final analyses since the age distribution at this site may not have been representative of the target population. The final study population of 892 men included 121 (13.6%) who were prospectively enrolled and 743 (83.3%) who were prospectively enrolled under separate protocols as well as 28 retrospective samples (3.1%). The study population included 706 initial (79.2%) and 159 repeat (17.8%) biopsies, and 27 men (3%) with an unknown biopsy history. At each institution an approximately equal number of men with (430 or 48.2%) and without (462 or 51.8%) PCa was enrolled. Participants and investigators were blinded to p2psa results and personnel at testing sites were blinded to individual clinical information. Testing Access Hybritech p2psa, PSA and fpsa assays were measured on the Access 2 Immunoassay Analyzer. Thus, our results apply to Access Hybritech p2psa, PSA and fpsa assays on the Access Immunoassay System. Serum samples were collected, processed within 8 hours and stored frozen at 70C or less before testing, which allowed accurate PHI measurement. 20 The p2psa assay was run in duplicate. Evaluation of the first replicate compared to the mean of duplicates using Passing-Bablock regression

3 1652 [-2]PRO-PROSTATE SPECIFIC ANTIGEN FOR PROSTATE CANCER DETECTION analysis showed no difference (Spearman s r ). The p2psa assay is a 2-site immunoenzymatic sandwich assay that uses specific monoclonal antibodies and 6 calibrators from 0 to 5,000 pg/ml. Statistical Analysis Minimum sample size was estimated as 295 patients without PCa to detect a 10% difference in specificity between PHI and percent fpsa at 0.05 and Also, a minimum sample size of 350 patients with PCa was determined to accurately estimate sensitivity at 95% with 95% CI less than 3%. Target sample size was increased to 400 participants per group. The primary null hypothesis was that PHI has no greater specificity than the free-to-total PSA ratio at 95% sensitivity. This hypothesis was tested using bootstrap based ROC analysis. 21 Briefly, 1,000 data sets of patients with benign conditions and those with PCa were generated to repetitively sample the study population Differences in the specificity between PHI and free-to-total PSA at 95% sensitivity were calculated for the 1,000 pairs of replicate data sets. The SE of the difference in specificity was then estimated with adjustment for correlation between the 2 tests. Finally, the bootstrap estimated SE was used to evaluate whether the difference in specificity was greater than 0, assuming normal distribution of the differences. A 1-sided statistical test was used for this analysis. This method was also used to compare the specificity of PHI and free-to-total PSA at 90%, 85% and 80% sensitivity. The secondary null hypothesis, which was that the ROC AUC of PHI was equal to that of free-to-total PSA, was tested by evaluating whether the difference between their estimated AUCs equaled 0 using empirical methods. 25,26 The AUCs of PHI and free-to-total PSA were also estimated for each prostate volume tertile to determine whether the observed trend in AUCs differed by prostate volume. The validity of pooling data across sites was evaluated by fitting a logistic regression model with PCa status as the dependent variable using PHI and site as independent predictors, including interaction terms for site and PHI. Comparisons between participant subgroups were made using the Wilcoxon rank sum test for continuous variables and the chi-square test for categorical variables. Two-sided statistical tests were used in all analyses except as noted with statistical significance considered at p All analysis was done using SAS, version 9.2. Individual Risk Assessment A 25% PCa detection rate was previously reported in men with PSA 2.0 to 10.0 ng/ml. 3 Since the proportion of PCa was determined by design, direct calculation of PCa probability would have resulted in inflated estimates for detecting PCa. Therefore, to obtain more accurate risk estimates for PCa we adjusted the proportion of PCa to 25% by repetitively sampling the study population 1,000 times. Each replicate data set consisted of 462 benign (75%) and 154 cancer (25%) cases The mean probability of cancer in the bootstrapped data sets for each PHI range was used as the point estimate and bootstrap estimated SEs were used to calculate 95% CIs. Likewise, RR estimates were calculated for each replicate data set by dividing the probability of PCa in each PHI range by that of PHI 0 to The mean RR and bootstrap estimated SEs were used to calculate the risk estimate and 95% CIs. PHI and Gleason Score Of participants with PCa we calculated the proportion in each PHI range with Gleason score 7 or greater. Risk ratios were estimated by dividing the probability of Gleason 7 or greater in each PHI range by that of PHI 0 to The Cochrane-Armitage test for trend was used to determine whether increasing PHI ranges corresponded to increasing the probability of Gleason 7 or greater PCa. ROC analysis was used to evaluate the clinical usefulness of PHI to detect PCa with Gleason scores greater than or equal to RESULTS Participants PHI and p2psa were significantly higher in patients with PCa than in controls while fpsa and free-tototal PSA were lower. Total PSA and age were comparable between the groups. Of the participants 89.8% underwent 12-core or greater biopsy and 98% underwent 10-core or greater biopsy. Overall 30.6%, 49.9% and 19.6% of participants were 50 to 59, 60 to 69 and 70 to 84 years old, respectively. Also, no interaction terms in the statistical model to evaluate heterogeneity by site was significant, supporting data pooling across sites. There were no significant differences in age (p 0.123), PSA (p 0.106), p2psa (p 0.088), free-to-total PSA (p 0.125) or PHI (p 0.848) between white and black men. ROC Results The figure shows sensitivity and specificity for all observed PSA, fpsa, p2psa, free-to-total PSA and PHI cutoffs in the 2.0 to 10.0 ng/ml PSA range. At 95% sensitivity the specificity of PHI was 16.0% compared to 8.4% for free-to-total PSA (p 0.015), 7.6% for p2psa, 6.5% for PSA and 3.5% for fpsa, rejecting the primary null hypothesis. At lower 90%, 85% and 80% sensitivity for PCa detection PHI specificity was significantly greater than that of free-tototal PSA, including 26% vs 18% (p 0.036), 39% vs 28% (p 0.006) and 45% vs 37% (p 0.031), respectively. The AUC of PCa detection was significantly greater for PHI (AUC 0.703) than for free-to-total PSA (AUC 0.648, p 0.004), fpsa (AUC 0.615), p2psa (AUC 0.557) or PSA (AUC 0.525), rejecting the secondary null hypothesis. Individual Risk Assessment Higher PHI values were associated with an increased risk of PCa detection (see table). Of the study population 25%, 33%, 30% and 13% had a PHI of 0 to 24.9, 25.0 to 34.9, 35.0 to 54.9 and 55.0 or greater, respectively. Compared to PHI less than

4 [-2]PRO-PROSTATE SPECIFIC ANTIGEN FOR PROSTATE CANCER DETECTION 1653 PHI Association with Gleason score. PHI also had a significant relationship with biopsy Gleason score (r 0.138, p 0.004). Of participants with PCa biopsy Gleason score was less than 7 in 290 (67.6%) and 7 or greater in 139 (32.4%). The probability of Gleason score 7 or greater PCa increased with increasing PHI (p 0.013, see table). The AUC of PHI exceeded that of free-to-total PSA (0.724 vs 0.670) in discriminating Gleason score greater than or equal to vs lower grade PCa or negative biopsy. Relationship with TRUS volume. The AUCs of PHI exceeded those of free-to-total PSA in all 3 prostate volume tertiles, that is 38 or less, 39 to 53 and 54 cc or greater (first tertile AUC vs 0.614, second tertile AUC vs and third tertile AUC vs 0.559). Excluded Participant Evaluation The AUCs of PHI with and without the excluded site were and 0.703, respectively. The AUCs of free-to-total PSA were and 0.648, respectively. PSA, fpsa, [-2]proPSA, free-to-total PSA and PHI (phi) ROC curves in 2 to 10 ng/ml PSA range show sensitivity 1 specificity at sequential cutoffs the RR of PCa detection on biopsy was 1.6, 3.0 and 4.7-fold higher at PHI 25.0 to 34.9, 35.0 to 54.9 and 55.0 or greater, respectively. Overall PHI 55.0 or greater was associated with a 52.1% probability of PCa. Age and PCa Probability Higher PHI was also associated with higher PCa risk estimates in each age group. The probability range of PCa was 10.9% (PHI 0 to 24.9) to 53.4% (PHI greater than 55) (RR 4.9) at ages 50 to 59 years, 12.5% (PHI 0 to 24.9) to 54.5% (PHI greater than 55) (RR 4.4) at ages 60 to 69 years and 5.8% (PHI 0 to 24.9) to 44.8% (PHI greater than 55) (RR 7.7) at ages greater than 70 years. DISCUSSION Prostate biopsy is routinely recommended for suspicious DRE regardless of PSA. 3 Biopsy is also recommended using PSA thresholds of 2.5 to 4.0 ng/ ml. 1,2,14 However, this leads to unnecessary biopsies and possible over detection of some cancers To elucidate whether PHI PSA isoform measurement could improve PCa early detection we examined a large, prospective cohort to predict biopsy findings in patients with moderate PSA elevations and nonsuspicious DRE. Prostate biopsy may be associated with discomfort, anxiety and financial costs. Minor complications occur frequently and major complications are possible, underscoring the need for more specific markers to decrease unnecessary biopsy. We determined the usefulness of p2psa and PHI for this clinical goal. PCa probability risk assessment using PHI and PHI relationship with biopsy Gleason score PHI Range Risk: % PCa probability (95% CI) 11.0 ( ) 18.1 ( ) 32.7 ( ) 52.1 ( ) RR (95% CI) ( ) 3.0 ( ) 4.7 ( ) % Pts Biopsy Gleason score:* No. less than 7 (%) 34 (73.9) 74 (71.8) 116 (69.9) 66 (57.9) No. 7 or greater (%) 12 (26.1) 29 (28.2) 50 (30.1) 48 (42.1) RR (95% CI) (0.61, 1.92) 1.15 (0.67, 1.98) 1.61 (0.95, 2.75) * One participant excluded with missing Gleason score (Cochran-Armitage test for trend p 0.01).

5 1654 [-2]PRO-PROSTATE SPECIFIC ANTIGEN FOR PROSTATE CANCER DETECTION Precursor forms of PSA improve the accuracy of PSA for detecting PCa. 5,6,9 12,27,28 Preliminary reports suggest that p2psa may be useful at PSA 2.0 to 10.0 ng/ml. 6,9 12,27,28 Some but not all studies suggest an association between propsa and PCa aggressiveness. 10,12,19 Thus, p2psa and PHI are being investigated in active surveillance programs to help decrease overtreatment of insignificant PCa. 18,29 Catalona et al previously reported that the propsa-to-fpsa ratio yielded higher specificity than the free-to-total PSA ratio. 9 Results in a separate multisite study also supported the role of p2psa combined with PSA and fpsa to decrease unnecessary biopsies. 12,13 In the current study specificity for PHI was higher than for free-to-total PSA at all prespecified sensitivities and the PCa risk increased with increasing PHI values. This suggests a role for PHI as a patient monitoring tool since increasing PHI values reflect PCa risk. 18 For example, at 95% sensitivity the specificity of PHI was 16.0% compared to 8.4% for free-to-total PSA. At lower sensitivities (90%, 85% and 80%) for PCa detection PHI had a significantly greater specificity than free-to-total PSA. These results were consistent across age groups, PSA concentrations and ethnic groups. For individual risk assessment the probability of PCa varied considerably based on PHI. For example, a man with PHI greater than 55 had a greater than 52% probability of PCa and 4.7-fold increased RR of positive biopsy. In contrast, at approximately 90% sensitivity a patient with PHI less than 25 had an 11% probability of PCa. In the PCa group higher PHI was also significantly associated with a higher percent of biopsy Gleason grade 7 or greater. In the entire study population the AUC of PHI exceeded that of free-to-total PSA (0.724 vs 0.670) to discriminate Gleason score greater than or equal to PCa vs lower Gleason grade PCa or negative biopsy. At a PHI cutoff of 21.3 Gleason score was 7 or greater in 25% of missed cancers. Thus, careful surveillance is needed. The AUCs of PHI also exceeded those of free-to-total PSA in all 3 prostate volume tertiles, suggesting that PHI improves PCa detection compared to free-to-total PSA across the spectrum of prostate volumes. Since PHI did not differ by age and race, these results suggest that PHI may be broadly applicable as an adjunct to predict clinically significant PCa. The strengths of the current validation study are the large number of participants and sites, providing confidence in the PHI cutoffs determined. PHI is highly effective when used in patients with moderately increased PSA, who may be most likely to benefit from early diagnosis and curative PCa treatment, and avoid unnecessary biopsy. A study limitation is that we did not evaluate the addition of PHI to predictive nomograms, which are often used for prostate cancer risk assessment. Future studies are warranted to examine this issue. Also, PSA was the primary indication for biopsy in this study, which should be considered when evaluating the ROC results. In addition, since p2psa and PHI were not used as the indications for biopsy in this study, future randomized trials would be useful to evaluate their use in screening compared to current protocols. CONCLUSIONS The PHI measurement, [-2]proPSA/fPSA PSA 1/2, may be useful to decrease unnecessary biopsies with improved specificity at various sensitivities for PCa detection in men 50 years or older with PSA 2.0 to 10.0 ng/ml and negative DRE findings. Our results apply to the Access Hybritech p2psa, PSA and fpsa assays on the Access Immunoassay System. 30 ACKNOWLEDGMENTS Drs. Alain Artus, Claude Darte, Bianca Gago, Malu Macairan, Simpa Salami, Edward F. Vonesh and Mark Wildhagen, and Jessica Banks, Willeke Bolle, Gerardina Bueti, Janna Chamberlin, Phillip Cooper, Renu Dua, Willard Dunn, Debra Elliott, Marcia Goodmanson, Robin Gurganus, Donghui Kan, Joep Kurstjens, Maureen Lemens, Lisa Ledebuhr, Lori Lofaro, Kathleen Loveland, Jiuliu Lu, Leslie Mangold, Patricia Nunnelly, Daniel O Brien, Kellie Paich, Mindy Rawlins, Javed Siddiqui and Sara Wyness assisted with the study. REFERENCES 1. Krumholtz JS, Carvalhal GF, Ramos CG et al: Prostate-specific antigen cutoff of 2.6 ng/ml for prostate cancer screening is associated with favorable pathologic tumor features. Urology 2002; 60: Thompson IM, Pauler DK, Goodman PJ et al: Prevalence of prostate cancer among men with a prostate-specific antigen level or 4.0 ng per milliliter. N Engl J Med 2004; 350: Catalona WJ, Richie JP, Ahmann FR et al: Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 1994; 151: Lilja H, Christensson A, Dahlen U et al: Prostatespecific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem 1991; 37: Catalona WJ, Partin AW, Slawin KM et al: Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998; 279: 1542.

6 [-2]PRO-PROSTATE SPECIFIC ANTIGEN FOR PROSTATE CANCER DETECTION Mikolajczyk SD, Catalona WJ, Evans CL et al: Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer. Clin Chem 2004; 50: Mikolajczyk SD, Grauer LS, Millar LS et al: A precursor form of PSA (ppsa) is a component of the free PSA in prostate cancer serum. Urology 1997; 50: Chan TY, Mikolajczyk SD, Lecksell K et al: Immunohistochemical staining of prostate cancer with monoclonal antibodies to the precursor of prostate-specific antigen. Urology 2003; 62: Catalona WJ, Bartsch G, Rittenhouse HG et al: Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml. J Urol 2003; 170: Catalona WJ, Bartsch G, Rittenhouse HG et al: Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen. J Urol 2004; 171: Sokoll LJ, Chan DW, Mikolajczyk SD et al: Proenzyme PSA for the early detection of prostate cancer in the ng/ml total PSA range: preliminary analysis. Urology 2003; 61: Sokoll LJ, Wang Y, Feng Z et al: [-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study. J Urol 2008; 180: Sokoll LJ, Sanda MG, Feng Z et al: A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev 2010; 19: Schröder FH, Hugosson J, Roobol MJ et al: Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: Andriole GL, Grubb RL 3rd, Buys SS et al: Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360: Welch HG and Albertsen PC: Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: J Natl Cancer Inst 2009; 101: Hugosson J, Carlsson S, Aus G et al: Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010; 11: Makarov DV, Isharwal S, Sokoll LJ et al: Proprostate-specific antigen measurements in serum and tissue are associated with treatment necessity among men enrolled in expectant management for prostate cancer. Clin Cancer Res 2009; 15: Jansen FH, van Schaik RH, Kurstjens J et al: Prostate-specific antigen (PSA) isoform p2psa in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol 2010; 57: Semjonow A, Kopke T, Eltze E et al: Pre-analytical in-vitro stability of [-2]proPSA in blood and serum. Clin Biochem 2010; 43: Qin G, Hsu YS and Zhou XH: New confidence intervals for the difference between two sensitivities at a fixed level of specificity. Stat Med 2006; 25: Hosmer DW and Lemeshow S: Applied Logistic Regression. New York: John Wiley & Sons Efron B: The Jackknife, the Bootstrap, and Other Resampling Plans. Philadelphia: Society for Industrial and Applied Mathematics Efron B: Better bootstrap confidence intervals. J Am Stat Assoc 1987; 82: Pepe MS: The Statistical Evaluation of Medical Tests for Classification and Prediction. New York: Oxford University Press DeLong ER, DeLong DM and Clarke-Pearson DL: Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988; 44: de Vries SH, Raaijmakers R, Blijenberg BG et al: Additional use of [-2] precursor prostate-specific antigen and benign PSA at diagnosis in screendetected prostate cancer. Urology 2005; 65: Naya Y, Fritsche HA, Bhadkamkar VA et al: Evaluation of precursor prostate-specific antigen isoform ratios in the detection of prostate cancer. Urol Oncol 2005; 23: Isharwal S, Makarov DV, Sokoll LJ et al: Prostate Health Index and diagnostic biopsy tissue DNA content combination improves accuracy to predict the need for prostate cancer treatment among men enrolled in a proactive surveillance program. Unpublished data. 30. Loeb S, Chan DW, Sokoll L et al: Prostate specific antigen assay standardization bias could affect clinical decision making. J Urol 2008; 180: 1959.

The 4Kscore blood test for risk of aggressive prostate cancer

The 4Kscore blood test for risk of aggressive prostate cancer The 4Kscore blood test for risk of aggressive prostate cancer Prostate cancer tests When to use the 4Kscore Test? Screening Prior to 1 st biopsy Prior to negative previous biopsy Prognosis in Gleason 6

More information

Prostate Health Index Literature

Prostate Health Index Literature Prostate Health Index Literature Update June 2013 Preoperative Prostate-Specific Antigen Isoform p2psa and Its Derivatives, %p2psa and Prostate Health Index, Predict Pathologic Outcomes in Patients Undergoing

More information

The 4Kscore blood test for risk of aggressive prostate cancer

The 4Kscore blood test for risk of aggressive prostate cancer The 4Kscore blood test for risk of aggressive prostate cancer Early detection of aggressive prostate cancer Challenges Serum PSA has a high false positive rate Over 1 million prostate biopsies performed

More information

1. What is the prostate-specific antigen (PSA) test?

1. What is the prostate-specific antigen (PSA) test? 1. What is the prostate-specific antigen (PSA) test? Prostate-specific antigen (PSA) is a protein produced by the cells of the prostate gland. The PSA test measures the level of PSA in the blood. The doctor

More information

An Empirical Evaluation of Guidelines on Prostate-specific Antigen Velocity in Prostate Cancer Detection

An Empirical Evaluation of Guidelines on Prostate-specific Antigen Velocity in Prostate Cancer Detection DOI: 10.1093/jnci/djr028 ARTICLE JNCI djr028 MA JOURNAL NAME Art. No. CE Code The Author 2011. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

More information

PSA Testing 101. Stanley H. Weiss, MD. Professor, UMDNJ-New Jersey Medical School. Director & PI, Essex County Cancer Coalition. weiss@umdnj.

PSA Testing 101. Stanley H. Weiss, MD. Professor, UMDNJ-New Jersey Medical School. Director & PI, Essex County Cancer Coalition. weiss@umdnj. PSA Testing 101 Stanley H. Weiss, MD Professor, UMDNJ-New Jersey Medical School Director & PI, Essex County Cancer Coalition weiss@umdnj.edu September 23, 2010 Screening: 3 tests for PCa A good screening

More information

Advances in Diagnostic and Molecular Testing in Prostate Cancer

Advances in Diagnostic and Molecular Testing in Prostate Cancer Advances in Diagnostic and Molecular Testing in Prostate Cancer Ashley E. Ross MD PhD Assistant Professor Urology, Oncology, Pathology Johns Hopkins School of Medicine September 24, 2015 1 Disclosures

More information

Prostate Cancer Screening Guideline

Prostate Cancer Screening Guideline Prostate Cancer Screening Guideline Contents Prevention 2 Screening Recommendations 2 Shared Decision Making 2 Test Recommendations 3 Follow-up/Referral 3 Treatment Overview 4 Evidence Summary 4 References

More information

DECISION AID TOOL PROSTATE CANCER SCREENING WITH PSA TESTING

DECISION AID TOOL PROSTATE CANCER SCREENING WITH PSA TESTING DECISION AID TOOL PROSTATE CANCER SCREENING WITH PSA TESTING This booklet is what is often called a decision aid. The goals of a decision aid are to help people better understand their medical choices

More information

4/8/13. Pre-test Audience Response. Prostate Cancer 2012. Screening and Treatment of Prostate Cancer: The 2013 Perspective

4/8/13. Pre-test Audience Response. Prostate Cancer 2012. Screening and Treatment of Prostate Cancer: The 2013 Perspective Pre-test Audience Response Screening and Treatment of Prostate Cancer: The 2013 Perspective 1. I do not offer routine PSA screening, and the USPSTF D recommendation will not change my practice. 2. In light

More information

Historical Basis for Concern

Historical Basis for Concern Androgens After : Are We Ready? Mohit Khera, MD, MBA Assistant Professor of Urology Division of Male Reproductive Medicine and Surgery Scott Department of Urology Baylor College of Medicine Historical

More information

CLINICAL PRACTICE. Clinical Practice. The PSA Test

CLINICAL PRACTICE. Clinical Practice. The PSA Test Clinical Practice This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines,

More information

Prostate-Specific Antigen Based Screening: Controversy and Guidelines

Prostate-Specific Antigen Based Screening: Controversy and Guidelines Prostate-Specific Antigen Based Screening: Controversy and Guidelines Eric H. Kim and Gerald L. Andriole Institutional Address: Washington University School of Medicine 4960 Children's Place Campus Box

More information

Oncology: Prostate/Testis/Penis/Urethra. Variation in Prostate Cancer Detection Rates in a Statewide Quality Improvement Collaborative

Oncology: Prostate/Testis/Penis/Urethra. Variation in Prostate Cancer Detection Rates in a Statewide Quality Improvement Collaborative Oncology: Prostate/Testis/Penis/Urethra Variation in Prostate Cancer Detection Rates in a Statewide Quality Improvement Collaborative Christopher B. Riedinger, Paul R. Womble, Susan M. Linsell, Zaojun

More information

Virtual Mentor American Medical Association Journal of Ethics January 2011, Volume 13, Number 1: 10-15.

Virtual Mentor American Medical Association Journal of Ethics January 2011, Volume 13, Number 1: 10-15. Virtual Mentor American Medical Association Journal of Ethics January 2011, Volume 13, Number 1: 10-15. CLINICAL CASE The Debate Over Prostate Cancer Screening Guidelines Commentary by Karen E. Hoffman,

More information

PSA screening in asymptomatic men the debate continues www.bpac.org.nz keyword: psa

PSA screening in asymptomatic men the debate continues www.bpac.org.nz keyword: psa PSA screening in asymptomatic men the debate continues www.bpac.org.nz keyword: psa Key messages: PSA is present in the benign and malignant prostate There is currently no national screening programme

More information

Prostate Cancer Screening: Are We There Yet? March 2010 Andrew M.D. Wolf, MD University of Virginia School of Medicine

Prostate Cancer Screening: Are We There Yet? March 2010 Andrew M.D. Wolf, MD University of Virginia School of Medicine Prostate Cancer Screening: Are We There Yet? March 2010 Andrew M.D. Wolf, MD University of Virginia School of Medicine Case #1 A 55 yo white man with well-controlled hypertension presents for his annual

More information

ERSPC and PLCO Prostate Cancer Screening Studies: What Are the Differences?

ERSPC and PLCO Prostate Cancer Screening Studies: What Are the Differences? EUROPEAN UROLOGY 58 (2010) 46 52 available at www.sciencedirect.com journal homepage: www.europeanurology.com Editorial ERSPC and PLCO Prostate Cancer Screening Studies: What Are the Differences? Fritz

More information

PSA: Prostate Cancer Screening

PSA: Prostate Cancer Screening PSA: Prostate Cancer Screening 42 nd Annual Convention of the Philippines College of Physicians May 7, 2012, SMX Convention Center Jose Albert Cruz Reyes III, MD, FPCS, FPUA, DPBU Institute of Urology

More information

MEDICAL POLICY SUBJECT: PROSTATE CANCER SCREENING, DETECTION AND MONITORING

MEDICAL POLICY SUBJECT: PROSTATE CANCER SCREENING, DETECTION AND MONITORING MEDICAL POLICY PAGE: 1 OF: 8 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy criteria are not applied.

More information

PSA Screening and the USPSTF Understanding the Controversy

PSA Screening and the USPSTF Understanding the Controversy PSA Screening and the USPSTF Understanding the Controversy Peter C. Albertsen Division of Urology University of Connecticut Farmington, CT, USA USPSTF Final Report 1 Four Key Questions 1. Does PSA based

More information

Role of MRI in the Diagnosis of Prostate Cancer, A Proposal

Role of MRI in the Diagnosis of Prostate Cancer, A Proposal Clinical and Experimental Medical Sciences, Vol. 1, 2013, no. 3, 111 116 HIKARI Ltd, www.m-hikari.com Role of MRI in the Diagnosis of Prostate Cancer, A Proposal W. Akhter Research Fellow Urology, Bartshealth

More information

Biomarkers for Prostate Cancer. Eric Wallen, MD Department of Urology

Biomarkers for Prostate Cancer. Eric Wallen, MD Department of Urology Biomarkers for Prostate Cancer Eric Wallen, MD Department of Urology Disclosure MDxHealth Scientific Advisor 55-year-old man: Poor Guy Risk of prostate cancer? 1 in 6 Risk of prostate cancer death? 1 in

More information

Guidelines for Cancer Prevention, Early detection & Screening. Prostate Cancer

Guidelines for Cancer Prevention, Early detection & Screening. Prostate Cancer Guidelines for Cancer Prevention, Early detection & Screening Prostate Cancer Intervention Comments & Recommendations For primary prevention, it has been suggested that diets low in meat & other fatty

More information

The Centers for Medicare & Medicaid Services (CMS) seeks stakeholder comments on the following clinical quality measure under development:

The Centers for Medicare & Medicaid Services (CMS) seeks stakeholder comments on the following clinical quality measure under development: The Centers for Medicare & Medicaid Services (CMS) seeks stakeholder comments on the following clinical quality measure under development: Title: Non-Recommended PSA-Based Screening Description: The percentage

More information

BJUI. Study Type Diagnosis (exploratory cohort) Level of Evidence 2b OBJECTIVE

BJUI. Study Type Diagnosis (exploratory cohort) Level of Evidence 2b OBJECTIVE . 2010 BJU INTERNATIONAL Urological Oncology FREE-TO-TOTAL PSA RATIO AND PCA3 SCORE IN PREDICTING POSITIVE BIOPSIES PLOUSSARD ET AL. BJUI BJU INTERNATIONAL The prostate cancer gene 3 (PCA3) urine test

More information

Tumor Markers for Prostate Cancer: Update for 2012 IAD-Cechtuma 2012 Conference Usti nad Labem, Czech Republic April 1-3, 2012

Tumor Markers for Prostate Cancer: Update for 2012 IAD-Cechtuma 2012 Conference Usti nad Labem, Czech Republic April 1-3, 2012 Tumor Markers for Prostate Cancer: Update for 2012 IAD-Cechtuma 2012 Conference Usti nad Labem, Czech Republic April 1-3, 2012 Herbert A. Fritsche, Ph.D. Health Discovery Corporaton Houston, Texas hfritsche@healthdiscoverycorp.com

More information

Update on Prostate Cancer: Screening, Diagnosis, and Treatment Making Sense of the Noise and Directions Forward

Update on Prostate Cancer: Screening, Diagnosis, and Treatment Making Sense of the Noise and Directions Forward Update on Prostate Cancer: Screening, Diagnosis, and Treatment Making Sense of the Noise and Directions Forward 33 rd Annual Internal Medicine Update December 5, 2015 Ryan C. Hedgepeth, MD, MS Chief of

More information

Official reprint from UpToDate www.uptodate.com 2013 UpToDate

Official reprint from UpToDate www.uptodate.com 2013 UpToDate Official reprint from UpToDate www.uptodate.com 2013 UpToDate The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek

More information

Gleason Score. Oncotype DX GPS. identified for. about surveillance. time to get sophisticated

Gleason Score. Oncotype DX GPS. identified for. about surveillance. time to get sophisticated patient: MARK SMITH PSA 6.2 Gleason Score 6 Oncotype DX GPS 8 identified for active surveillance time to get sophisticated about surveillance Accurate prediction of prostate cancer risk is needed at the

More information

PSA Screening for Prostate Cancer Information for Care Providers

PSA Screening for Prostate Cancer Information for Care Providers All men should know they are having a PSA test and be informed of the implications prior to testing. This booklet was created to help primary care providers offer men information about the risks and benefits

More information

Prostate Cancer Screening. Dr. J. McCracken, Urologist

Prostate Cancer Screening. Dr. J. McCracken, Urologist Prostate Cancer Screening Dr. J. McCracken, Urologist USPSTF Lifetime risk for diagnosis currently estimated at 15.9% Llifetime risk of dying of prostate cancer is 2.8% Seventy percent of deaths due to

More information

Prostate Cancer 2014

Prostate Cancer 2014 Prostate Cancer 2014 Eric A. Klein, M.D. Chairman Glickman Urological and Kidney Institute Professor of Surgery Cleveland Clinic Lerner College of Medicine Incidence rates, US Men Mortality Rates, US Men

More information

Technologies To Detect Prostate Cancer

Technologies To Detect Prostate Cancer CHAPTER 3 Technologies To Detect Prostate Cancer he most commonly used technologies for detecting and diagnosing prostate cancer are digital rectal examination (DRE), prostate-specific antigen (PSA) measurement,

More information

A New Biomarker in Prostate Cancer Care: Oncotype Dx. David M Albala, MD Chief of Urology Crouse Hospital Syracuse, NY

A New Biomarker in Prostate Cancer Care: Oncotype Dx. David M Albala, MD Chief of Urology Crouse Hospital Syracuse, NY A New Biomarker in Prostate Cancer Care: Oncotype Dx David M Albala, MD Chief of Urology Crouse Hospital Syracuse, NY Learning Objectives Review the current challenges in the prediction and prognosis of

More information

The PLCO Trial Not a comparison of Screening vs no Screening

The PLCO Trial Not a comparison of Screening vs no Screening PSA Screening: Science, Politics and Uncertainty David F. Penson, MD, MPH Hamilton and Howd Chair of Urologic Oncology Professor and Chair, Department of Urologic Surgery Director, Center for Surgical

More information

Key Messages for Healthcare Providers

Key Messages for Healthcare Providers Cancer Care Ontario: Prostate Cancer Screening with the Prostate- Specific Antigen (PSA) Test Key Messages for Healthcare Providers Considerations for men at average risk Avoid prostate-specific antigen

More information

The PSA Controversy: Defining It, Discussing It, and Coping With It

The PSA Controversy: Defining It, Discussing It, and Coping With It The PSA Controversy: Defining It, Discussing It, and Coping With It 11 TH ANNUAL SYMPOSIUM ON MEN S HEALTH June 12, 2013 The PSA Controversy Defining It, Discussing It and Coping With It As of May 2012,

More information

Digital rectal examination as a prostate cancer-screening method in a country with a low incidence of prostate cancer

Digital rectal examination as a prostate cancer-screening method in a country with a low incidence of prostate cancer (2007) 10, 250 255 & 2007 Nature Publishing Group All rights reserved 1365-7852/07 $30.00 ORIGINAL ARTICLE www.nature.com/pcan Digital rectal examination as a prostate cancer-screening method in a country

More information

Prostate Cancer Management and Referral Guidance

Prostate Cancer Management and Referral Guidance Prostate Cancer Management and Referral Guidance The Prostate Cancer Management and Referral Guidance has been developed to help primary care health professionals manage men with symptoms suggestive of

More information

7. Prostate cancer in PSA relapse

7. Prostate cancer in PSA relapse 7. Prostate cancer in PSA relapse A patient with prostate cancer in PSA relapse is one who, having received a primary treatment with intent to cure, has a raised PSA (prostate-specific antigen) level defined

More information

Cancer in Primary Care: Prostate Cancer Screening. How and How often? Should we and in which patients?

Cancer in Primary Care: Prostate Cancer Screening. How and How often? Should we and in which patients? Cancer in Primary Care: Prostate Cancer Screening How and How often? Should we and in which patients? PLCO trial (Prostate, Lung, Colorectal and Ovarian) Results In the screening group, rates of compliance

More information

Prostate cancer screening: clinical applications and challenges

Prostate cancer screening: clinical applications and challenges Urologic Oncology: Seminars and Original Investigations 22 (2004) 353 357 Seminar article Prostate cancer screening: clinical applications and challenges Otis W. Brawley, M.D.* Winship Cancer Institute,

More information

Prostate cancer. Christopher Eden. The Royal Surrey County Hospital, Guildford & The Hampshire Clinic, Old Basing.

Prostate cancer. Christopher Eden. The Royal Surrey County Hospital, Guildford & The Hampshire Clinic, Old Basing. Prostate cancer Christopher Eden The Royal Surrey County Hospital, Guildford & The Hampshire Clinic, Old Basing. Screening Screening men for PCa (prostate cancer) using PSA (Prostate Specific Antigen blood

More information

Saturation Biopsy for Diagnosis and Staging of Prostate Cancer. Original Policy Date

Saturation Biopsy for Diagnosis and Staging of Prostate Cancer. Original Policy Date MP 7.01.101 Saturation Biopsy for Diagnosis and Staging of Prostate Cancer Medical Policy Section Surgery Issue 12/2013 Original Policy Date 12/2013 Last Review Status/Date /12/2013 Return to Medical Policy

More information

Prostate Cancer Screening: Phantom menace to society. Folusho Ogunfiditimi, DM, MPH, PA-C Vattikuti Urology Institute Henry Ford Health System

Prostate Cancer Screening: Phantom menace to society. Folusho Ogunfiditimi, DM, MPH, PA-C Vattikuti Urology Institute Henry Ford Health System Prostate Cancer Screening: Phantom menace to society Folusho Ogunfiditimi, DM, MPH, PA-C Vattikuti Urology Institute Henry Ford Health System Objectives USPTF Recommendations on PSA testing Justification

More information

Prostate Cancer Gene 3 (PCA3) the first highly specific genetic test* improves the diagnosis of prostate cancer. * CE marked

Prostate Cancer Gene 3 (PCA3) the first highly specific genetic test* improves the diagnosis of prostate cancer. * CE marked Prostate Cancer Gene 3 (PCA3) the first highly specific genetic test* improves the diagnosis of prostate cancer * CE marked Introduction Prostate biopsy dilemma Prostate cancer (PCa) is the most commonly

More information

Prostate Cancer Screening in Taiwan: a must

Prostate Cancer Screening in Taiwan: a must Prostate Cancer Screening in Taiwan: a must 吳 俊 德 基 隆 長 庚 醫 院 台 灣 醫 學 會 105 th What is the PSA test? The blood level of PSA is often elevated in men with prostate cancer, and the PSA test was originally

More information

Screening for Prostate Cancer

Screening for Prostate Cancer Screening for Prostate Cancer It is now clear that screening for Prostate Cancer discovers the disease at an earlier and more curable stage. It is not yet clear whether this translates into reduced mortality

More information

Abstract. Introduction

Abstract. Introduction Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) Significantly Improve Prostate Cancer Detection at Initial Biopsy in a Total PSA Range of 2 10 ng/ml Matteo Ferro 3,6., Dario Bruzzese 2.,

More information

Science Highlights. To PSA or not to PSA: That is the Question.

Science Highlights. To PSA or not to PSA: That is the Question. Science Highlights June 2012 by Ann A. Kiessling, PhD at the To PSA or not to PSA: That is the Question. The current raucous debate over the commonly used PSA blood test to screen for prostate cancer,

More information

Use Of Testosterone In Men With Prostate Cancer. Traditional view: T is dangerous for PCa

Use Of Testosterone In Men With Prostate Cancer. Traditional view: T is dangerous for PCa Use Of Testosterone In Men With Prostate Cancer Abraham Morgentaler, MD, FACS Director, Men s s Health Boston Associate Clinical Professor of Urology Harvard Medical School Boston, USA Traditional view:

More information

Us TOO University Presents: Understanding Diagnostic Testing

Us TOO University Presents: Understanding Diagnostic Testing Us TOO University Presents: Understanding Diagnostic Testing for Prostate Cancer Patients Today s speaker is Manish Bhandari, MD Program moderator is Pam Barrett, Us TOO International Made possible by

More information

What the U.S. Preventive Services Task Force Missed in Its Prostate Cancer Screening Recommendation

What the U.S. Preventive Services Task Force Missed in Its Prostate Cancer Screening Recommendation In the Balance 201207170 M12-0991 open early What the USPSTF Missed in Its Prostate Cancer Screening Recommendation What the U.S. Preventive Services Task Force Missed in Its Prostate Cancer Screening

More information

LOW LEVELS OF PROSTATE-SPECIFIC ANTIGEN PREDICT LONG-TERM RISK OF PROSTATE CANCER: RESULTS FROM THE BALTIMORE LONGITUDINAL STUDY OF AGING

LOW LEVELS OF PROSTATE-SPECIFIC ANTIGEN PREDICT LONG-TERM RISK OF PROSTATE CANCER: RESULTS FROM THE BALTIMORE LONGITUDINAL STUDY OF AGING ADULT UROLOGY CME ARTICLE LOW LEVELS OF PROSTATE-SPECIFIC ANTIGEN PREDICT LONG-TERM RISK OF PROSTATE CANCER: RESULTS FROM THE BALTIMORE LONGITUDINAL STUDY OF AGING JUNYONG FANG, E. JEFFREY METTER, PATRICIA

More information

An Introduction to PROSTATE CANCER

An Introduction to PROSTATE CANCER An Introduction to PROSTATE CANCER Being diagnosed with prostate cancer can be a life-altering experience. It requires making some very difficult decisions about treatments that can affect not only the

More information

Prostatectomy, pelvic lymphadenect. Med age 63 years Mean followup 53 months No other cancer related therapy before recurrence. Negative.

Prostatectomy, pelvic lymphadenect. Med age 63 years Mean followup 53 months No other cancer related therapy before recurrence. Negative. Adjuvante und Salvage Radiotherapie Ludwig Plasswilm Klinik für Radio-Onkologie, KSSG CANCER CONTROL WITH RADICAL PROSTATECTOMY ALONE IN 1,000 CONSECUTIVE PATIENTS 1983 1998 Clinical stage T1 and T2 Mean

More information

Prostate Cancer Management and Referral Guidance

Prostate Cancer Management and Referral Guidance Prostate Cancer Management and Referral Guidance Prostate Cancer Working Group and Ministry of Health. 2015. Prostate Cancer Management and Referral Guidance. Wellington: Ministry of Health. Published

More information

Electronic health records to study population health: opportunities and challenges

Electronic health records to study population health: opportunities and challenges Electronic health records to study population health: opportunities and challenges Caroline A. Thompson, PhD, MPH Assistant Professor of Epidemiology San Diego State University Caroline.Thompson@mail.sdsu.edu

More information

Testosterone Replacement Therapy and Prostate Risks: Where s the Beef?

Testosterone Replacement Therapy and Prostate Risks: Where s the Beef? Testosterone Replacement Therapy and Prostate Risks: Where s the Beef? Abraham Morgentaler, MD Division of Urology Beth Israel Deaconess Medical Center Harvard Medical School Boston, Massachusetts, USA

More information

Focus on PSA Screening for Prostate Cancer Vol. 28 Supplement, February 2012. Prostate Cancer: Should We Be Screening?

Focus on PSA Screening for Prostate Cancer Vol. 28 Supplement, February 2012. Prostate Cancer: Should We Be Screening? Focus on PSA Screening for Prostate Cancer Vol. 28 Supplement, February 2012 Prostate Cancer: Should We Be Screening? INSIDE THIS ISSUE 2 Why the Controversy? 3 Active Surveillance 4 The Radical Prostatectomy

More information

Prostate cancer volume at biopsy vs. findings at Prostatectomy

Prostate cancer volume at biopsy vs. findings at Prostatectomy Prostate cancer volume at biopsy vs. findings at Prostatectomy May 2005 By Shelly Smits, RHIT, CCS, CTR Ian Thompson, MD Data Source: Cancer registry data of prostate cancer treated with prostatectomy

More information

PSA TESTING FOR PROSTATE CANCER A CRICO/RMF DECISION SUPPORT TOOL

PSA TESTING FOR PROSTATE CANCER A CRICO/RMF DECISION SUPPORT TOOL PSA TESTING FOR PROSTATE CANCER A CRICO/RMF DECISION SUPPORT TOOL Created: 2008 Updated: 2009 PROSTATE-SPECIFIC ANTIGEN TESTING FOR PROSTATE CANCER A DECISION SUPPORT TOOL Prostate Cancer and Medical Malpractice

More information

Early Detection Research Network: Validation Infrastructure. Jo Ann Rinaudo, Ph.D. Division of Cancer Prevention

Early Detection Research Network: Validation Infrastructure. Jo Ann Rinaudo, Ph.D. Division of Cancer Prevention Early Detection Research Network: Validation Infrastructure Jo Ann Rinaudo, Ph.D. Division of Cancer Prevention 15 October 2015 Mission The NCI Early Detection Research Network s (EDRN) mission is to implement

More information

Detection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical

Detection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical Summary. 111 Detection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical recurrence (BCR) is the first sign of recurrent

More information

Screening for Prostate Cancer

Screening for Prostate Cancer Screening for Prostate Cancer Review against programme appraisal criteria for the UK National Screening Committee (UK NSC) Version 1: This document summarises the work of ScHARR 1 2 and places it against

More information

PSA Testing for Prostate Cancer An information sheet for men considering a PSA Test

PSA Testing for Prostate Cancer An information sheet for men considering a PSA Test PSA Testing for Prostate Cancer An information sheet for men considering a PSA Test What is the aim of this leaflet? Prostate cancer is a serious condition. The PSA test, which can give an early indication

More information

Update on Prostate Cancer Screening Guidelines

Update on Prostate Cancer Screening Guidelines www.medscape.com Update on Prostate Cancer Screening Guidelines Christine Gonzalez, PharmD, CHHC US Pharmacist Abstract and Introduction Introduction In the United States, prostate cancer is the most common

More information

UKNSC Screening for Prostate Cancer Review 2015 Update

UKNSC Screening for Prostate Cancer Review 2015 Update UKNSC Screening for Prostate Cancer Review 2015 Update Review against programme appraisal criteria for the UK National Screening Committee (UKNSC) November 2015 Prepared by: Dr Karly S Louie Queen Mary

More information

KIDNEY FUNCTION RELATION TO SIZE OF THE TUMOR IN RENAL CELL CANCINOMA

KIDNEY FUNCTION RELATION TO SIZE OF THE TUMOR IN RENAL CELL CANCINOMA KIDNEY FUNCTION RELATION TO SIZE OF THE TUMOR IN RENAL CELL CANCINOMA O.E. Stakhvoskyi, E.O. Stakhovsky, Y.V. Vitruk, O.A. Voylenko, P.S. Vukalovich, V.A. Kotov, O.M. Gavriluk National Canсer Institute,

More information

ACCEPTED MANUSCRIPT. Understanding the performance of active surveillance selection criteria in diverse urology practices

ACCEPTED MANUSCRIPT. Understanding the performance of active surveillance selection criteria in diverse urology practices Understanding the performance of active surveillance selection criteria in diverse urology practices Scott R. Hawken BS*,1, Paul R. Womble MD*,1, Lindsey A. Herrel MD 1, Zaojun Ye MS 1, Susan M. Linsell

More information

Cancer research in the Midland Region the prostate and bowel cancer projects

Cancer research in the Midland Region the prostate and bowel cancer projects Cancer research in the Midland Region the prostate and bowel cancer projects Ross Lawrenson Waikato Clinical School University of Auckland MoH/HRC Cancer Research agenda Lung cancer Palliative care Prostate

More information

Prostate Cancer Early Detection

Prostate Cancer Early Detection Clinical Prostate Cancer Early Detection Version 1.2004 Continue Panel Members * Richard Babaian, MD/Chair The University of Texas M.D. Anderson Cancer Center Ralph Hauke, MD UNMC Eppley Cancer Center

More information

PCa Commentary. Volume 73 January-February 2012 PSA AND TREATMENT DECISIONS:

PCa Commentary. Volume 73 January-February 2012 PSA AND TREATMENT DECISIONS: 1101 Madison Street Suite 1101 Seattle, WA 98104 P 206-215-2480 www.seattleprostate.com PCa Commentary Volume 73 January-February 2012 CONTENTS PSA SCREENING & BASIC SCIENCE PSA AND TREATMENT 1 DECISIONS

More information

Treatment of Incidental Prostate Cancer Diagnosed during BPH Surgery with Radical Prostatectomy: Appropriate or over Treatment?

Treatment of Incidental Prostate Cancer Diagnosed during BPH Surgery with Radical Prostatectomy: Appropriate or over Treatment? Journal of Cancer Therapy, 2012, 3, 256-262 http://dx.doi.org/10.4236/jct.2012.34036 Published Online August 2012 (http://www.scirp.org/journal/jct) Treatment of Incidental Prostate Cancer Diagnosed during

More information

Malpractice Litigation in the Setting of Prostate Cancer Diagnosis

Malpractice Litigation in the Setting of Prostate Cancer Diagnosis urologypracticejournal.com Malpractice Litigation in the Setting of Prostate Cancer Diagnosis Peter L. Sunaryo,* Marc Colaco, Ronald Davis and Hossein Sadeghi-Nejad From the Division of Urology, Department

More information

Endpoint Selection in Phase II Oncology trials

Endpoint Selection in Phase II Oncology trials Endpoint Selection in Phase II Oncology trials Anastasia Ivanova Department of Biostatistics UNC at Chapel Hill aivanova@bios.unc.edu Primary endpoints in Phase II trials Recently looked at journal articles

More information

Study Design and Statistical Analysis

Study Design and Statistical Analysis Study Design and Statistical Analysis Anny H Xiang, PhD Department of Preventive Medicine University of Southern California Outline Designing Clinical Research Studies Statistical Data Analysis Designing

More information

U.S. Preventive Services Task Force

U.S. Preventive Services Task Force U.S. Preventive Services Task Force Screening for Prostate Cancer: Recommendation Statement See related Putting Prevention into Practice on page 283. This summary is one in a series excerpted from the

More information

Corporate Medical Policy Saturation Biopsy for Diagnosis and Staging of Prostate Cancer

Corporate Medical Policy Saturation Biopsy for Diagnosis and Staging of Prostate Cancer Corporate Medical Policy Saturation Biopsy for Diagnosis and Staging of Prostate Cancer File Name: Origination: Last CAP Review: Next CAP Review: Last Review: saturation_biopsy_for_diagnosis_and_staging_of_prostate_cancer

More information

Diabetes Prevention in Latinos

Diabetes Prevention in Latinos Diabetes Prevention in Latinos Matthew O Brien, MD, MSc Assistant Professor of Medicine and Public Health Northwestern Feinberg School of Medicine Institute for Public Health and Medicine October 17, 2013

More information

Genomic Basis of Prostate Cancer Health Disparity Among African-American

Genomic Basis of Prostate Cancer Health Disparity Among African-American AD AWARD NUMBER: W81XWH-12-1-0259 TITLE: Men Genomic Basis of Prostate Cancer Health Disparity Among African-American PRINCIPAL INVESTIGATOR: Harry Ostrer, M.D. RECIPIENT: Albert Einstein College of Medicine

More information

Establishing a Cohort of African-American Men to Validate a Method for using Serial PSA Measures to Detect Aggressive Prostate Cancers

Establishing a Cohort of African-American Men to Validate a Method for using Serial PSA Measures to Detect Aggressive Prostate Cancers Establishing a Cohort of African-American Men to Validate a Method for using Serial PSA Measures to Detect Aggressive Prostate Cancers James R. Hebert, Sc.D., Cancer Prevention and Control Program, University

More information

2. Contact Person: Garo Mimaryan, MS., RAC 7 Technical Regulatory Affairs Specialist III 3. Phone Number: (914)-524-3270

2. Contact Person: Garo Mimaryan, MS., RAC 7 Technical Regulatory Affairs Specialist III 3. Phone Number: (914)-524-3270 SIEM EN S Abbreviated 510(k) Premnarket Notification IMMULITE 2000 PSA Calibration Verification Material 6. 510(k) Summary as Required by 21 CFR 807.92 K( - is-1 3 (v A. 5 10(k) Number: B. Purpose for

More information

PCA3 Score and Prostate Cancer Diagnosis at Repeated Saturation Biopsy. Which cut-off: 20 or 35?

PCA3 Score and Prostate Cancer Diagnosis at Repeated Saturation Biopsy. Which cut-off: 20 or 35? ORIGINAL Article Vol. 38 (4): 489-495, July - August, 2012 PCA3 Score and Prostate Cancer Diagnosis at Repeated Saturation Biopsy. Which cut-off: 20 or 35? Pietro Pepe, Filippo Fraggetta, Antonio Galia,

More information

PSA Test Provides the Early Prostate Cancer Detection That Has Saved the Life of Thousands of Men

PSA Test Provides the Early Prostate Cancer Detection That Has Saved the Life of Thousands of Men PSA Test Provides the Early Prostate Cancer Detection That Has Saved the Life of Thousands of Men Table of Contents 1. What the research shows on the effectiveness of the PSA test p. 2 2. PSA test guidelines

More information

TO SCREEN OR NOT TO SCREEN: THE PROSTATE CANCER

TO SCREEN OR NOT TO SCREEN: THE PROSTATE CANCER TO SCREEN OR NOT TO SCREEN: THE PROSTATE CANCER DILEMMA Thomas J Stormont MD January 2012 http://www.youtube.com/watch?v=8jd 7bAHVp0A&feature=related related INTRODUCTION A government health panel (the

More information

Molecular markers and clinical trial design parallels between oncology and rare diseases?

Molecular markers and clinical trial design parallels between oncology and rare diseases? Molecular markers and clinical trial design parallels between oncology and rare diseases?, Harriet Sommer Institute for Medical Biometry and Statistics, University of Freiburg Medical Center 6. Forum Patientennahe

More information

Published Ahead of Print on July 16, 2012 as 10.1200/JCO.2012.43.3441. J Clin Oncol 30. 2012 by American Society of Clinical Oncology

Published Ahead of Print on July 16, 2012 as 10.1200/JCO.2012.43.3441. J Clin Oncol 30. 2012 by American Society of Clinical Oncology Published Ahead of Print on July 16, 2012 as 10.1200/JCO.2012.43.3441 The latest version is at http://jco.ascopubs.org/cgi/doi/10.1200/jco.2012.43.3441 JOURNAL OF CLINICAL ONCOLOGY A S C O S P E C I A

More information

In 2006 approximately 234,000 men were diagnosed with

In 2006 approximately 234,000 men were diagnosed with Long-Term Survival in Men With High Grade Prostate Cancer: A Comparison Between Conservative Treatment, Radiation Therapy and Radical Prostatectomy A Propensity Scoring Approach Ashutosh Tewari,*, George

More information

Prostate Cancer Early Detection

Prostate Cancer Early Detection Clinical in Oncology Prostate Cancer Early Detection V.2.2007 Continue www.nccn.org Panel Members * Mark H. Kawachi, MD/Chair City of Hope Cancer Center Robert R. Bahnson, MD Arthur G. James Cancer Hospital

More information

Analysis of Prostate Cancer at Easter Connecticut Health Network Using Cancer Registry Data

Analysis of Prostate Cancer at Easter Connecticut Health Network Using Cancer Registry Data The 2014 Cancer Program Annual Public Reporting of Outcomes/Annual Site Analysis Statistical Data from 2013 More than 70 percent of all newly diagnosed cancer patients are treated in the more than 1,500

More information

Predominance of ERG negative high grade prostate cancers in African American men

Predominance of ERG negative high grade prostate cancers in African American men 982 Predominance of ERG negative high grade prostate cancers in African American men JAMES FARRELL 1,2, DENISE YOUNG 1, YONGMEI CHEN 1, JENNIFER CULLEN 1, INGER L. ROSNER 1,2, JACOB KAGAN 3, SUDHIR SRIVASTAVA

More information

Screening for Prostate Cancer

Screening for Prostate Cancer clinical practice Screening for Prostate Cancer Richard M. Hoffman, M.D., M.P.H. This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies

More information

ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)

ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) 3 Integrated Trials Testing Targeted Therapy in Early Stage Lung Cancer Part of NCI s Precision Medicine Effort in

More information

Raising cut-off value of prostate specific antigen (PSA) for biopsy in symptomatic men in India to reduce unnecessary biopsy

Raising cut-off value of prostate specific antigen (PSA) for biopsy in symptomatic men in India to reduce unnecessary biopsy Indian J Med Res 139, June 2014, pp 851-856 Raising cut-off value of prostate specific antigen (PSA) for biopsy in symptomatic men in India to reduce unnecessary biopsy Shalini Agnihotri, R.D. Mittal,

More information

Clinical Practice Guidelines

Clinical Practice Guidelines Clinical Practice Guidelines Prostate Cancer Screening CareMore Quality Management CareMore Health System adopts Clinical Practice Guidelines for the purpose of improving health care and reducing unnecessary

More information

THE RISK DISTRIBUTION CURVE AND ITS DERIVATIVES. Ralph Stern Cardiovascular Medicine University of Michigan Ann Arbor, Michigan. stern@umich.

THE RISK DISTRIBUTION CURVE AND ITS DERIVATIVES. Ralph Stern Cardiovascular Medicine University of Michigan Ann Arbor, Michigan. stern@umich. THE RISK DISTRIBUTION CURVE AND ITS DERIVATIVES Ralph Stern Cardiovascular Medicine University of Michigan Ann Arbor, Michigan stern@umich.edu ABSTRACT Risk stratification is most directly and informatively

More information